10 results about "Allograft rejection" patented technology

The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

Disclosed are compositions and methods for preventing graft versus host disease (GVHD) or allograft rejection in subjects receiving donor cells. Also disclosed are methods enhancing regulatory T (Treg) cells for use in preventing GVHD. Also disclosed are methods of suppressing alloreactive donor cells in a subject receiving transplant donor cells that involves adoptive transfer of the treated Treg cells. Also disclosed are enhanced Treg cells produced by the disclosed methods that have been engineered to express chimeric antigen receptor (CAR) polypeptide cells.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

The disclosure provides uses of anti-CD40 ligand antibodies for immunosuppression in islet cell transplantation in subjects having type 1 diabetes (T1D). The disclosure also provides uses of compounds that block the interaction between CD40 and CD40 ligand, including such anti-CD40 ligand antibodies and antigen binding fragments thereof, for preventing or reducing islet cell allograft rejection in subjects having T1D, for restoring physiological insulin secretion or hypoglycemia awareness in a subject having T1D, or for treating subjects having T1D and / or treating subjects having T1D and partial graft function of islet cells where the subjects have had a previous allogenic islet cell transplant.

Compositions that include a cationic peptide hydrogel and an immunosuppressive small molecule drug are described. The small molecule drug is crystallized and dispersed in the peptide hydrogel to allow for slow release of the drug. Methods of inhibiting allograft rejection and treating autoimmune-mediated organ damage by local administration of the peptide hydrogel compositions are described.

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and / or activity. e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.

Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.